Dr. Powell Discusses the Next Steps for CPI-613

Video

In Partnership With:

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Following a phase I trial, researchers plan to move forward with CPI-613, focusing on myelodysplastic syndrome. In the study, 3/3 patients with very refractory disease responded to treatment, which is encouraging, Powell says, though represents just a hint of activity.

CPI-613 will also be analyzed in acute myeloid leukemia, where activity was seen, in combination with high-dose cytarabine. Cytarabine is an effective treatment for patients with relapsed/refractory disease and the combination will be evaluated for tolerance and efficacy.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD